Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS ; volume:10 ; number:1 ; day:11 ; month:9 ; year:2023 ; pages:1-22 ; date:12.2023
EJNMMI Physics ; 10, Heft 1 (11.9.2023), 1-22, 12.2023
- Creator
-
Rumiantcev, Mikhail
Li, Wei Bo
Lindner, Simon
Liubchenko, Grigory
Resch, Sandra
Bartenstein, Peter
Ziegler, Sibylle I.
Böning, Guido
Delker, Astrid
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40658-023-00567-2
- URN
-
urn:nbn:de:101:1-2024020808533180678125
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rumiantcev, Mikhail
- Li, Wei Bo
- Lindner, Simon
- Liubchenko, Grigory
- Resch, Sandra
- Bartenstein, Peter
- Ziegler, Sibylle I.
- Böning, Guido
- Delker, Astrid
- SpringerLink (Online service)
Other Objects (12)
Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC
Der diagnostische Nutzen der 68Ga-PSMA-HBED-CC PET/CT in der Primärdiagnostik des Prostatakarzinoms
Toxizität und Effektivität der Kombinationstherapie mit dem mTOR‑Inhibitor Everolimus und [177Lu]Lu-DOTA-TATE im Vergleich mit den Einzeltherapien im Kleintiermodell
Einfluss einer Vorbehandlung mit Lithium, Anabolikum und Hypertransfusion auf die Regeneration der Hämatopoese bei der Maus nach Strahlenschaden
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC
Der diagnostische Nutzen der 68Ga-PSMA-HBED-CC PET/CT in der Primärdiagnostik des Prostatakarzinoms
Toxizität und Effektivität der Kombinationstherapie mit dem mTOR‑Inhibitor Everolimus und [177Lu]Lu-DOTA-TATE im Vergleich mit den Einzeltherapien im Kleintiermodell
Einfluss einer Vorbehandlung mit Lithium, Anabolikum und Hypertransfusion auf die Regeneration der Hämatopoese bei der Maus nach Strahlenschaden
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC
Der diagnostische Nutzen der 68Ga-PSMA-HBED-CC PET/CT in der Primärdiagnostik des Prostatakarzinoms
Toxizität und Effektivität der Kombinationstherapie mit dem mTOR‑Inhibitor Everolimus und [177Lu]Lu-DOTA-TATE im Vergleich mit den Einzeltherapien im Kleintiermodell
Einfluss einer Vorbehandlung mit Lithium, Anabolikum und Hypertransfusion auf die Regeneration der Hämatopoese bei der Maus nach Strahlenschaden
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T